Skip to content

US · SCLXW · DRUG MANUFACTURERS - GENERAL

Scilex Holding Company (SCLXW) intrinsic value and stock valuation

$0.05as of 2026-11-21 · Mkt cap 58.87M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Scilex Holding Company DCF and intrinsic value

InvestorsCraft values SCLXW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SCLXW’s statements →

Scilex Holding Company Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - General Palo Alto, CA 94303 scilexholding.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$30.3M+5.1% 5y CAGRd
20192025
Net income
-$-358.73M
20192025
Free cash flow
$3.68M
20192025
Total equity
-$-211.75M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$30.3M$56.6M$46.7M$38M$31.3M
Operating income-$-272.3M-$-83.4M-$-105.43M-$-50.63M-$-35.84M
Net income-$-358.73M-$-72.81M-$-114.33M-$-23.36M-$-88.42M
EPSd-$-32.52M-$-10.48M-$-30.73M-$-6.1M-$-23.27M
Operating cash flow$3.82M$19.4M-$-20.71M-$-21.26M-$-28.66M
Capital expenditure-$-130K-$-600K-$-330K-$-2.07M$0.00
Free cash flow$3.68M$18.8M-$-21.04M-$-23.32M-$-28.66M
Total assets$365M$93M$101.3M$86.5M$77.9M
Total debt$132.5M$38M$128.5M$1.41M$154.8M
Net debt$127.6M$34.7M$124.5M-$-770K$150.4M
Total equity-$-211.75M-$-192.64M-$-172.94M$36.2M-$-223.88M
Cash and short-term investments$11M$3.27M$3.92M$2.18M$4.34M
Income statement
20252024202320222021
Revenue$30.3M$56.6M$46.7M$38M$31.3M
Cost of revenue$15.2M$16.7M$15.7M$10.8M$3.63M
Gross profit$15M$39.9M$31.1M$27.2M$27.7M
Research and development expenses$20.7M$9.64M$12.8M$9.05M$9.2M
Selling, general and administrative expenses$266.6M$119M$119.6M$64.9M$50.6M
Other expenses$0.00-$-5.36M$4.11M$3.92M$3.74M
Operating expenses$287.3M$123.3M$136.5M$77.9M$63.5M
Cost and expenses$302.6M$140M$152.2M$88.7M$67.2M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$11.5M$1.96M$1.07M$9.6M$11.8M
Depreciation and amortization$4.62M$4.05M$4.15M$4.45M$3.78M
Ebitda-$-357.94M-$-66.8M-$-109.1M-$-9.3M-$-72.88M
Operating income-$-272.3M-$-83.4M-$-105.43M-$-50.63M-$-35.84M
Total other income/expenses, net-$-101.72M$10.6M-$-8.89M$27.3M-$-52.58M
Income before tax-$-374.03M-$-72.81M-$-114.32M-$-23.36M-$-88.42M
Income tax expense$30K-$0.00$10K$0.00$10K
Net income-$-358.73M-$-72.81M-$-114.33M-$-23.36M-$-88.42M
Weighted average shares outstanding$11M$6.95M$3.72M$3.83M$3.8M
Weighted average diluted shares outstanding$11M$6.95M$3.72M$3.83M$3.8M
Balance sheet
20252024202320222021
Cash and short-term investments$11M$3.27M$3.92M$2.18M$4.34M
Net receivables$15.2M$26.4M$34.6M$21.2M$14.3M
Inventory$4.79M$2.44M$4.21M$1.38M$2.56M
Total current assets$38.4M$41.6M$46.8M$29.6M$23M
Property, plant and equipment, net$28.4M$2.93M$3.67M$1.9M$2.11M
Goodwill and intangible assets$72.6M$45.9M$50M$54.1M$52.3M
Long-term investments$1M$2.42M$810K$0.00$0.00
Total non-current assets$326.6M$51.4M$54.5M$56.9M$54.9M
Total assets$365M$93M$101.3M$86.5M$77.9M
Accounts payable$86.3M$52.6M$41M$8.45M$4.28M
Short-term debt$92.3M$35.6M$109.2M$740K$58.1M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$483.7M$259.6M$250.4M$44.8M$169.4M
Long-term debt$40.3M$2.37M$19.3M$670K$96.7M
Deferred revenue, non-current$0.00$2.69M$0.00$0.00$5.19M
Total non-current liabilities$93.1M$26M$23.9M$5.45M$132.4M
Capital lease obligations$13.2M$2.24M$3M$1.41M$1.65M
Total liabilities$576.7M$285.6M$274.3M$50.3M$301.8M
Common stock$0.00$20K$20K$10K$10K
Retained earnings-$-921.79M-$-563.05M-$-490.25M-$-375.91M-$-352.55M
Accumulated other comprehensive income (loss)-$-5.8M$6.32M$0.00-$0.00$0.00
Total equity-$-211.75M-$-192.64M-$-172.94M$36.2M-$-223.88M
Total investments$7.03M$2.42M$810K$0.00$0.00
Total debt$132.5M$38M$128.5M$1.41M$154.8M
Net debt$127.6M$34.7M$124.5M-$-770K$150.4M
Cash flow statement
20252024202320222021
Net income-$-358.73M-$-72.81M-$-114.33M-$-23.36M-$-88.42M
Depreciation and amortization$4.62M$4.05M$4.15M$3.96M$3.78M
Stock-based compensation$15.5M$15.7M$14.6M$5.28M$5.82M
Change in working capital$114M$64.8M$65.8M$45.7M$13.6M
Accounts receivable$13.8M-$-6.27M-$-13.36M-$-6.97M-$-1.14M
Inventory$1.8M$1.46M-$-2.84M$1.18M-$-1.42M
Accounts payable$13.1M$7.42M$19.9M$2.81M-$-3.84M
Net cash provided by operating activities$3.82M$19.4M-$-20.71M-$-21.26M-$-28.66M
Investments in property, plant and equipment-$-130K-$-600K-$-30K-$-2.07M$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$4.08M-$-2.67M-$-330K-$-2.07M$0.00
Common stock issued$27.9M$44.6M$35.5M$100K$0.00
Common stock repurchased$0.00$0.00-$-10M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-5.46M-$-18.13M$23.6M$21.2M$28.2M
Net change in cash$1.68M-$-1.46M$2.54M-$-2.15M-$-500K
Cash at end of period$4.96M$3.27M$4.73M$2.18M$4.34M
Operating cash flow$3.82M$19.4M-$-20.71M-$-21.26M-$-28.66M
Capital expenditure-$-130K-$-600K-$-330K-$-2.07M$0.00
Free cash flow$3.68M$18.8M-$-21.04M-$-23.32M-$-28.66M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Scilex Holding Company

        Scilex Holding Company operates as a biopharmaceutical firm primarily engaged in creating and distributing non-opioid treatments for individuals suffering from acute and chronic pain conditions. Its flagship product, ZTlido 1.8%, is a prescription-only topical lidocaine formulation designed to alleviate neuropathic pain, specifically that associated with post-herpetic neuralgia, a type of nerve pain occurring after a shingles infection. The company's development pipeline also features SP-102, known as SEMDEXA, a viscous corticosteroid gel administered via epidural injections. This candidate is currently in Phase 3 clinical trials, targeting lumbosacral radicular pain. Another investigational drug, SP-103, aims to treat low back pain and is progressing through Phase 2 clinical trials. Additionally, SP-104, an innovative low-dose, delayed-release naltrexone hydrochloride formulation, is in Phase 1 clinical development for managing fibromyalgia. Scilex Holding Company is headquartered in Palo Alto, California, and functions as a subsidiary of Sorrento Therapeutics, Inc.

        CEO
        Henry H. Ji
        Employees
        34
        Beta
        1.74

        Explore

        Frequently asked questions

        What is the intrinsic value of Scilex Holding Company (SCLXW)?

        InvestorsCraft does not currently publish an intrinsic value for SCLXW. How the IC value is calculated.

        Is SCLXW undervalued?

        InvestorsCraft does not publish an undervaluation signal for SCLXW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.